钙拮抗药应用状况分析Analysis of the use of calcium antagonist
赖宝龙,任斌,陈孝
LAI Bao-long;REN Bin;CHEN Xiao (Dept.of Pharmacy;
摘要(Abstract)：
目的 了解钙拮抗药在广东省的医院的应用状况及其变化趋势。方法 对广东省医院 2 0 0 0 - 2 0 0 2年 3代钙拮抗药用药金额 ,及其普通片剂、缓释和控释制剂用药频度 (DDDs) ,日均费用进行统计和分析。结果 2 0 0 0 - 2 0 0 2年钙拮抗药每年销售金额呈增长趋势 ,增长幅度放缓 ;以长效、高效、降压平稳、服用方便为特点的缓释、控释制剂和第 3代钙拮抗药占此类药物应用的绝大部分份额 ,约为总销售金额的 85 % ;硝苯地平片处于DDDs排序第 1位 ,表明该药在钙拮抗药的应用中占有重要地位 ;氨氯地平片日均费用最高 ,但销售金额居首位 ,DDDs逐年增高。结论 广东省的医院钙拮抗药的应用比较合理
Objective To investigate the current situation and developing of the use of Calcium Antagonist in hospitals of Guangdong. Methods To investigate three generation Calcium Antagonist used during the past three years in respect to the sum of money of consumption, DDDs and daily cost. Results The increasing rate of consumption sum of calcium antagonist during the period 2000-2002 has been decreased. The main market was occupied by sustained released agents and control-released agents which were characterized as long-effect, strong potency, smooth action and convenient administration. Nifedipine ranked in the first place of DDDS, being very important in the use of Calcium Antagonist. Amlodipine was the highest in the daily cost of calcium antagonist, however, it took the first place in the list of sum of money and its DDDS increased. Conclusions The use of Calcium Antagonist is rational in Guangdong .
关键词(KeyWords)：
钙拮抗药;用药金额;DDDs;日均费用
calcium antagonist; sum of money of consumption; DDDs;daily cost
基金项目(Foundation):
作者(Authors):
赖宝龙,任斌,陈孝
LAI Bao-long;REN Bin;CHEN Xiao (Dept.of Pharmacy;
参考文献(References)：
- [1]邹豪、邵元福、朱才娟,等.医院药品DDD数排序分析的原理及应用[J].中国药房,1996,7(5):215-217.
- [2]李大魁,张继春,杨根治,等.医院用药经济分析的基本方法[J].中国药房,1996,7(2):71-73.
- [3]BrownMJ,PalmerCR ,CastaigneA ,etal.Morbidityandmortalityinpatientsrandomi zedtodouble blindtreatmentwithlong actingcalciumchannelblockerordiureticintheinternationalNifedipineGITSStudy:InterventionasaGoalinHypertensiontreatment(INSI GHT).Lancet,200,356:366-372.
- [4]王宏宇,胡大一.钙拮抗药在抗高血压治疗中的地位[J].新医学,2003,34(3):142-143.